Lessons Learned: David Perry, from Chemdex to Anacor

01 Jun 2006

• By Roger Longman

Six years ago, David Perry was one of the rock stars of the Web, the founding CEO of Chemdex-Ventro. He stuck with it as the company unraveled, shutting down most of the businesses he'd built, and merging the remainder into what is now an OTC-traded software company. Now he's applying the lessons he learned to his current company, Anacor Pharmaceuticals, a start-up which has discovered a small handful of now clinical-stage compounds.

Six years ago, David Perry was one of the rock stars of the Web, the founding CEO of Chemdex-Ventro, one of the creators of the business-to-business e-marketplace concept. In just three years, he had built his company from scratch to 354 employees and an unaccountable $10 billion valuation. And then he stuck with it as the company unraveled, shutting down most of the businesses he'd built, and merging the remainder into what is now an OTC-traded software company.

But Perry didn't nurse his disappointment for very long. And he's thought long and hard about what happened at Chemdex, why it happened, and how he can apply the lessons...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

22 May 2025

• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

22 May 2025

• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.